Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin C  COVID-19 treatment studies for Vitamin C  C19 studies: Vitamin C  Vitamin C   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Progression 5% Improvement Relative Risk Improvement 50% Discharge 22% c19early.org/c Coppock et al. Vitamin C for COVID-19 RCT LATE TREATMENT Is late treatment with vitamin C beneficial for COVID-19? RCT 66 patients in the USA Greater improvement (p=0.16) and higher discharge (p=0.071), not stat. sig. Coppock et al., Life, doi:10.3390/life12030453 Favors vitamin C Favors control
Pharmacologic Ascorbic Acid as Early Therapy for Hospitalized Patients with COVID-19: A Randomized Clinical Trial
Coppock et al., Life, doi:10.3390/life12030453
Coppock et al., Pharmacologic Ascorbic Acid as Early Therapy for Hospitalized Patients with COVID-19: A Randomized Clinical.., Life, doi:10.3390/life12030453
Mar 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
RCT with 66 very late stage (8 days from symptom onset) hospitalized patients, 44 treated with vitamin C and 22 control patients, showing no significant differences with treatment.
risk of progression, 5.0% lower, HR 0.95, p = 0.64, treatment 4 of 44 (9.1%), control 2 of 22 (9.1%), adjusted per study, within 36 hours.
risk of no improvement, 49.7% better, RR 0.50, p = 0.16, treatment 6 of 44 (13.6%), control 6 of 22 (27.3%), NNT 7.3, adjusted per study, inverted to make RR<1 favor treatment, odds ratio converted to relative risk, within 36 hours.
risk of no hospital discharge, 22.5% lower, RR 0.78, p = 0.07, treatment 31 of 44 (70.5%), control 20 of 22 (90.9%), NNT 4.9, within 36 hours.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Coppock et al., 19 Mar 2022, Randomized Controlled Trial, USA, peer-reviewed, 14 authors, average treatment delay 8.1 days.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin CAll
Abstract: life Article Pharmacologic Ascorbic Acid as Early Therapy for Hospitalized Patients with COVID-19: A Randomized Clinical Trial Dagan Coppock 1, * , Pierre-Christian Violet 2 , Gustavo Vasquez 1 , Katherine Belden 1 , Michael Foster 3 , Bret Mullin 3 , Devon Magee 3 , Isabelle Mikell 4 , Lokesh Shah 4 , Victoria Powers 4 , Brian Curcio 5 , Constantine Daskalakis 5 , Daniel Monti 6 and Mark Levine 2, * 1 2 3 4 5 6   Citation: Coppock, D.; Violet, P.-C.; Vasquez, G.; Belden, K.; Foster, M.; Mullin, B.; Magee, D.; Mikell, I.; Shah, L.; Powers, V.; et al. Pharmacologic Ascorbic Acid as Early Therapy for Hospitalized Patients with COVID-19: A Randomized Clinical Trial. Life 2022, 12, 453. https:// doi.org/10.3390/life12030453 Academic Editor: Ramón Cacabelos Received: 29 January 2022 Accepted: 15 March 2022 Published: 19 March 2022 Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in * Division of Infectious Diseases, Department of Medicine, Sidney Kimmel Medical College, Thomas Jefferson University, 1015 Chestnut Street, Philadelphia, PA 19107, USA; gvasquezmd@gmail.com (G.V.); katherine.belden@jefferson.edu (K.B.) Molecular and Clinical Nutrition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA; pierre-christian.violet@nih.gov Jefferson Clinical Research Institute, Thomas Jefferson University, 833 Chestnut Street, Philadelphia, PA 19107, USA; mfoster610@gmail.com (M.F.); bret.mullin@jefferson.edu (B.M.); devon.magee@jefferson.edu (D.M.) Sidney Kimmel Medical College, Thomas Jefferson University, 1015 Walnut Street, Philadelphia, PA 19107, USA; isabelle.mikell@students.jefferson.edu (I.M.); lokesh.shah@students.jefferson.edu (L.S.); tori.powers@students.jefferson.edu (V.P.) Division of Biostatistics, Department of Pharmacology and Experimental Therapeutics, Sidney Kimmel Medical College, Thomas Jefferson University, 1015 Chestnut Street, Philadelphia, PA 19107, USA; curciob@arcadia.edu (B.C.); constantine.daskalakis@jefferson.edu (C.D.) Department of Integrative Medicine and Nutritional Sciences, Sidney Kimmel Medical College, Thomas Jefferson University, 925 Chestnut Street, Philadelphia, PA 19107, USA; daniel.monti@jefferson.edu Correspondence: dagan.coppock@jefferson.edu (D.C.); markl@bdg8.niddk.nih.gov (M.L.) Abstract: Despite the widespread availability of effective vaccines, new cases of infection with severe acute respiratory syndrome coronavirus-2, the cause of coronavirus disease 2019 (COVID-19), remain a concern in the settings of vaccine hesitancy and vaccine breakthrough. In this randomized, controlled, phase 2 trial, we hypothesized that high-dose ascorbic acid delivered intravenously to achieve pharmacologic concentrations may target the high viral phase of COVID-19 and thus improve early clinical outcomes. Sixty-six patients admitted with COVID-19 and requiring supplemental oxygen were randomized to receive either escalating doses of intravenous ascorbic acid plus standard of care or standard of care alone. The demographic and clinical characteristics were well-balanced between the two study arms. The primary outcome evaluated in this study was clinical improvement at 72 h after randomization. While the primary outcome was not achieved, point estimates for the composite outcome and its individual components of decreased use of supplemental oxygen, decreased use of bronchodilators,..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit